Results 261 to 270 of about 133,463 (299)
Some of the next articles are maybe not open access.
BRAF and MEK inhibition in melanoma
Expert Opinion on Drug Safety, 2015Selective inhibition of the MAPK pathway with either BRAF or MEK inhibition has emerged as a key component for the treatment of BRAF-mutant metastatic melanoma. New evidence suggests that the combination of BRAF and MEK inhibitors improves tumor response rate and progression-free survival, while potentially attenuating some of the serious adverse ...
Lesly A, Dossett +2 more
openaire +2 more sources
The clinical development of MEK inhibitors
Nature Reviews Clinical Oncology, 2014Aberrant activation of the RAS-RAF-MEK-ERK1/2 pathway occurs in more than 30% of human cancers. As part of this pathway, MEK1 and MEK2 have crucial roles in tumorigenesis, cell proliferation and inhibition of apoptosis and, therefore, MEK1/2 inhibition is an attractive therapeutic strategy in a number of cancers.
Yujie, Zhao, Alex A, Adjei
openaire +2 more sources
MEK and MAF in myeloma therapy
Blood, 2011Despite increased understanding of molecular pathogenesis of multiple myeloma and implementation of therapies such as bortezomib and thalidomide, only 10% of patients survive more than 10 years after diagnosis. Until recently, new therapies for myeloma have not been developed based on a detailed understanding of the molecular pathology of the disease ...
Relja, Popovic, Jonathan D, Licht
openaire +2 more sources
MEK Inhibition in BRAF-Mutated Melanoma
New England Journal of Medicine, 2012Korrespondenz zu 10.1056 ...
Flaherty, Keith T. +2 more
openaire +4 more sources
MEK Inhibition Overcomes Chemoimmunotherapy Resistance by Inducing CXCL10 in Cancer Cells
Cancer Cell, 2022Philippe Joubert +2 more
exaly
MEK Inhibitor Resistance Mechanisms and Recent Developments in Combination Trials
Cancer Treatment Reviews, 2021David Gershenson +2 more
exaly